Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SMMT |
---|---|---|
09:32 ET | 43965 | 4.57 |
09:34 ET | 1629 | 4.5101 |
09:36 ET | 2101 | 4.48 |
09:39 ET | 1692 | 4.47 |
09:41 ET | 5097 | 4.435 |
09:43 ET | 500 | 4.44 |
09:45 ET | 12440 | 4.46 |
09:48 ET | 21430 | 4.485 |
09:50 ET | 643 | 4.45 |
09:52 ET | 1100 | 4.44 |
09:54 ET | 1000 | 4.435 |
09:56 ET | 2200 | 4.445 |
09:57 ET | 2881 | 4.45 |
09:59 ET | 2274 | 4.45 |
10:01 ET | 1821 | 4.44 |
10:03 ET | 1308 | 4.455 |
10:06 ET | 300 | 4.47 |
10:08 ET | 1300 | 4.47 |
10:10 ET | 7798 | 4.49 |
10:12 ET | 9185 | 4.49 |
10:14 ET | 628 | 4.48 |
10:15 ET | 1200 | 4.475 |
10:17 ET | 5969 | 4.46 |
10:19 ET | 800 | 4.45 |
10:21 ET | 2100 | 4.465 |
10:24 ET | 3249 | 4.465 |
10:26 ET | 1052 | 4.445 |
10:28 ET | 3389 | 4.44 |
10:30 ET | 1229 | 4.445 |
10:32 ET | 3631 | 4.46 |
10:33 ET | 200 | 4.465 |
10:35 ET | 1327 | 4.465 |
10:37 ET | 1328 | 4.475 |
10:39 ET | 1227 | 4.455 |
10:42 ET | 200 | 4.45 |
10:44 ET | 200 | 4.455 |
10:46 ET | 700 | 4.455 |
10:48 ET | 4239 | 4.465 |
10:50 ET | 495 | 4.465 |
10:51 ET | 200 | 4.465 |
10:53 ET | 512 | 4.465 |
10:55 ET | 300 | 4.4644 |
10:57 ET | 100 | 4.465 |
11:00 ET | 4526 | 4.46 |
11:02 ET | 4495 | 4.48 |
11:04 ET | 300 | 4.485 |
11:06 ET | 2200 | 4.5 |
11:08 ET | 100 | 4.5002 |
11:09 ET | 903 | 4.495 |
11:11 ET | 1916 | 4.49 |
11:13 ET | 300 | 4.49 |
11:15 ET | 2432 | 4.495 |
11:18 ET | 100 | 4.495 |
11:20 ET | 400 | 4.49 |
11:22 ET | 700 | 4.495 |
11:26 ET | 3072 | 4.52 |
11:27 ET | 12122 | 4.485 |
11:29 ET | 8756 | 4.505 |
11:31 ET | 3019 | 4.515 |
11:33 ET | 300 | 4.515 |
11:36 ET | 3047 | 4.515 |
11:38 ET | 900 | 4.52 |
11:40 ET | 200 | 4.525 |
11:42 ET | 1857 | 4.525 |
11:44 ET | 1300 | 4.535 |
11:45 ET | 494 | 4.535 |
11:47 ET | 200 | 4.525 |
11:49 ET | 2342 | 4.52 |
11:51 ET | 794 | 4.52 |
11:54 ET | 4279 | 4.52 |
11:56 ET | 1270 | 4.51 |
11:58 ET | 400 | 4.515 |
12:00 ET | 802 | 4.515 |
12:02 ET | 2938 | 4.53 |
12:03 ET | 200 | 4.535 |
12:07 ET | 708 | 4.545 |
12:09 ET | 11275 | 4.565 |
12:12 ET | 5294 | 4.55 |
12:14 ET | 1423 | 4.525 |
12:16 ET | 2956 | 4.52 |
12:18 ET | 1700 | 4.5256 |
12:20 ET | 4374 | 4.5289 |
12:21 ET | 1634 | 4.525 |
12:23 ET | 2058 | 4.52 |
12:27 ET | 1055 | 4.5299 |
12:30 ET | 700 | 4.53 |
12:32 ET | 200 | 4.535 |
12:34 ET | 300 | 4.535 |
12:36 ET | 300 | 4.535 |
12:38 ET | 3626 | 4.555 |
12:39 ET | 1700 | 4.555 |
12:41 ET | 2237 | 4.555 |
12:43 ET | 331 | 4.555 |
12:45 ET | 518 | 4.56 |
12:48 ET | 6241 | 4.545 |
12:50 ET | 1159 | 4.545 |
12:52 ET | 1700 | 4.545 |
12:54 ET | 431 | 4.545 |
12:56 ET | 1500 | 4.555 |
12:57 ET | 100 | 4.56 |
12:59 ET | 723 | 4.5529 |
01:01 ET | 4081 | 4.541 |
01:03 ET | 659 | 4.54 |
01:06 ET | 1300 | 4.53 |
01:08 ET | 100 | 4.535 |
01:10 ET | 698 | 4.535 |
01:12 ET | 100 | 4.53 |
01:14 ET | 3870 | 4.5383 |
01:15 ET | 200 | 4.5325 |
01:17 ET | 1044 | 4.53 |
01:19 ET | 1659 | 4.5318 |
01:21 ET | 300 | 4.53 |
01:24 ET | 225 | 4.535 |
01:26 ET | 100 | 4.53 |
01:28 ET | 1486 | 4.525 |
01:30 ET | 400 | 4.525 |
01:33 ET | 327 | 4.525 |
01:35 ET | 1000 | 4.52 |
01:37 ET | 3129 | 4.5201 |
01:39 ET | 3869 | 4.52 |
01:42 ET | 500 | 4.525 |
01:44 ET | 3600 | 4.52 |
01:46 ET | 8009 | 4.52 |
01:50 ET | 23245 | 4.53 |
01:51 ET | 1400 | 4.535 |
01:53 ET | 9622 | 4.525 |
01:55 ET | 5214 | 4.52 |
01:57 ET | 100 | 4.51 |
02:00 ET | 700 | 4.52 |
02:02 ET | 4615 | 4.53 |
02:04 ET | 200 | 4.525 |
02:06 ET | 300 | 4.525 |
02:08 ET | 300 | 4.52 |
02:09 ET | 4784 | 4.52 |
02:11 ET | 7069 | 4.53 |
02:13 ET | 100 | 4.53 |
02:15 ET | 541 | 4.52 |
02:18 ET | 200 | 4.52 |
02:20 ET | 400 | 4.525 |
02:22 ET | 2727 | 4.54 |
02:24 ET | 286 | 4.54 |
02:26 ET | 200 | 4.535 |
02:27 ET | 115 | 4.54 |
02:29 ET | 4702 | 4.53 |
02:31 ET | 1340 | 4.515 |
02:33 ET | 2550 | 4.535 |
02:36 ET | 528 | 4.53 |
02:40 ET | 200 | 4.525 |
02:42 ET | 200 | 4.525 |
02:44 ET | 1491 | 4.525 |
02:45 ET | 100 | 4.525 |
02:47 ET | 2500 | 4.52 |
02:49 ET | 2065 | 4.5199 |
02:54 ET | 962 | 4.52 |
02:56 ET | 1900 | 4.53 |
02:58 ET | 1150 | 4.525 |
03:00 ET | 455 | 4.525 |
03:02 ET | 3855 | 4.53 |
03:03 ET | 440 | 4.525 |
03:05 ET | 500 | 4.53 |
03:07 ET | 4829 | 4.54 |
03:09 ET | 4330 | 4.5238 |
03:12 ET | 4476 | 4.53 |
03:14 ET | 1000 | 4.525 |
03:16 ET | 329 | 4.53 |
03:18 ET | 1500 | 4.5251 |
03:20 ET | 579 | 4.525 |
03:21 ET | 4150 | 4.52 |
03:23 ET | 3678 | 4.53 |
03:25 ET | 500 | 4.525 |
03:30 ET | 8025 | 4.505 |
03:32 ET | 5678 | 4.49 |
03:34 ET | 1500 | 4.495 |
03:36 ET | 8672 | 4.52 |
03:38 ET | 500 | 4.52 |
03:39 ET | 7122 | 4.515 |
03:41 ET | 14645 | 4.505 |
03:43 ET | 9119 | 4.49 |
03:45 ET | 6446 | 4.5 |
03:48 ET | 1867 | 4.505 |
03:50 ET | 13976 | 4.505 |
03:52 ET | 9129 | 4.515 |
03:54 ET | 13541 | 4.525 |
03:56 ET | 32120 | 4.545 |
03:57 ET | 25836 | 4.53 |
03:59 ET | 240510 | 4.54 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Summit Therapeutics Inc | 3.1B | -27.4x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
Xenon Pharmaceuticals Inc | 3.0B | -14.9x | --- |
Apogee Therapeutics Inc | 2.9B | -25.6x | --- |
Biohaven Ltd | 3.3B | -5.8x | --- |
IDEAYA Biosciences Inc | 3.1B | -20.2x | --- |
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.1B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 702.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -1.26 |
EPS | $-0.17 |
Book Value | $0.11 |
P/E Ratio | -27.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.